- Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
- Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
- Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
- Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- Pliant Therapeutics to Participate in Upcoming Investor Events
- Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
- Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
- Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
- Pliant Therapeutics to Participate in Upcoming Investor Conferences
- Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
More ▼
Key statistics
On Tuesday, Pliant Therapeutics Inc (PLRX:NSQ) closed at 12.88, 14.90% above the 52 week low of 11.21 set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.98 |
---|---|
High | 13.02 |
Low | 12.75 |
Bid | 10.00 |
Offer | 12.88 |
Previous close | 12.88 |
Average volume | 602.84k |
---|---|
Shares outstanding | 60.33m |
Free float | 56.46m |
P/E (TTM) | -- |
Market cap | 777.00m USD |
EPS (TTM) | -2.86 USD |
Data delayed at least 15 minutes, as of May 28 2024 21:00 BST.
More ▼